help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on May 18, 2006
Molecular Endocrinology, doi:10.1210/me.2005-0510
Molecular Endocrinology Vol. 0, No. 2006 200505101-
doi:10.1210/me.2005-0510
Copyright © 2006 by the Endocrine Society.
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
20/10/2493    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leung, M. Y.-K.
Right arrow Articles by Chan, W.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leung, M. Y.-K.
Right arrow Articles by Chan, W.-Y.

Submitted on December 13, 2005
Accepted on May 8, 2006

BIOLOGICAL EFFECT OF A NOVEL MUTATION IN THE THIRD LEUCINE-RICH REPEAT OF HUMAN LUTEINIZING HORMONE RECEPTOR

Michael Yiu-Kwong Leung, Peter J. Steinbach, Deborah Bear, Vanessa Baxendale, Patricia Y. Fechner, Owen M Rennert, and Wai-Yee Chan*

Laboratory of Clinical Genomics, National Institute of Child Health and Human Development, and Center for Molecular Modeling, Division of Computational Bioscience, Center for Information Technology, National Institutes of Health, Bethesda, MD 20892; Department of Pediatrics, Stanford University, Stanford, CA 94305, U.S.A.; Department of Pediatrics, Georgetown University, Washington, DC 20007

* To whom correspondence should be addressed. E-mail: chanwy{at}mail.nih.gov.

A novel heterozygous mutation A340T leading to the substitution of Phe for the conserved amino acid Ile-114 was identified by nucleotide sequencing of the human LH/chorionic gonadotropin receptor (hLHR) of a patient with Leydig Cell Hypoplasia (LCH). This mutation is located in the third leucine-rich repeat (LRR) in the ectodomain of the hLHR. In vitro expression studies demonstrated that this mutation results in reduced ligand binding and signal transduction of the receptor. Studies of hLHR constructs where various amino acids were substituted for the conserved Ile-114 showed that receptor activity is sensitive to changes in size, shape, and charge of the side chain. A homology model of the wild-type hLHR ectodomain was made, illustrating the packing of conserved hydrophobic side chains in the protein core. Substitution of Ile-114 by Phe might disrupt intermolecular contacts between hormone and receptor. This mutation might also affect an LHR-dimer interaction. Thus, the I114F mutation reduces ligand binding and signal transduction by the hLHR, and it is partially responsible for LCH in the patient.


Key words: LH receptor • Leucine rich repeats • loss-of-function mutation • Leydig cell Hypolasia • molecular model







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society